“The implementation of pharmacological treatments” for heart failure “has been shown to improve patient clinical outcomes in large trials.” These are the conclusions of the ‘Bring-up 3 Heart Failure’ study presented during the 55th National Cardiology Congress of the National Association of Hospital Cardiologists (Anmco), the most important cardiology event in Italy, which is taking place in Rimini.
“The Bring-Up 3 Heart Failure – underlines Fabrizio Oliva, president of Anmco and director of Cardiology 1 of the Niguarda hospital in Milan – is a study now in its third edition, since in the context of heart failure two clinical studies have already been conducted with the same approach methodological In this case, a total of 5,203 patients diagnosed with heart failure were included, coming from 186 cardiology centers. 74% of the cases were patients enrolled during outpatient evaluations and, therefore, with forms of heart failure. chronic. The remaining 26% of patients – continues Oliva – were included upon discharge from hospitalization for heart failure and, therefore, it is possible to know the diagnostic/therapeutic management methods in the acute in-hospital phase the average of the entire patient population included in the ‘Bring-up Heart Failure’ is 70 years old and 21% are female. Globally, 60% of the patients with heart failure included in the study have reduced left ventricular systolic function. The study, of which the first phase has been completed, has already provided precise information on the management methods of this patient population both in the hospital and outpatient context.”
“56% of the outpatient population – continues the Anmco president – had heart failure with reduced systolic function (HFrEF); in these patients a lower average age and a lower representation of the female sex are confirmed, with important comorbidity data, 30% diabetes, 68% dyslipidemia, 35% renal failure The most frequent etiology in HFrEF is ischemic and approximately 40% of patients have had previous revascularization. In patients with preserved systolic function the most frequent etiologies are hypertension and valvulopathies”.
“Compared to the past, among laboratory tests there is a greater use of the evaluation of natriuretic peptides, while martial deficiency is investigated in few patients. The undoubtedly most significant data – Oliva focuses – concerns the treatments recommended by the guidelines: in HFrEF at the baseline visit these therapies are implemented and over 96% of patients are on beta-blocker, over 90% on Raas inhibitor therapy, 80% on Mras and 84% on Sglt2i. 64% of patients are on quadruple therapy. Even in HFpEF the percentage of patients in Sglt2i increases from 25% to 50%. In patients hospitalized for acute decompensation compared to admission there is a significant increase in treatments recommended at the time of discharge”.
“These important results – concludes iOliva – confirm the quality of Italian cardiology, but also the importance of Anmco observational research which leads to the implementation of pharmacological treatments which have proven capable of improving the clinical outcomes of these patients in large trials” .
#Italian #study #heart #failure #implementing #treatments #improves #outcomes
